.STUDY HIGHLIGHT.06 August 2024.
A sizable randomized regulated trial with cisgender females highlights the difficulties of faithfulness to a regular oral preexposure prophylaxis program and also demonstrates that twice-yearly shot of lenacapavir can maintain reliable HIV protection levels over 6 months.